Galeterone (TOK-001 or VN/124-1) is an experimental drug being developed by Tokai Pharmaceuticals Inc. for the treatment of prostate cancer. It is both an androgen receptor antagonist and CYP17A1 inhibitor. It is currently being tested in early phase I/II clinical trials for castration resistant prostate cancer.
This page contains content from the copyrighted Wikipedia article "Galeterone"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
